Amlodipine Cost in Wyoming 2026

What Does Amlodipine Actually Cost in Wyoming?

Generic amlodipine is one of the least expensive prescription medications available in Wyoming. Cash-pay prices at retail pharmacies across Cheyenne, Casper, Laramie, and Gillette run approximately $8 per month for a 30-tablet supply of 5 mg or 10 mg. The brand-name product, Norvasc (manufactured by Pfizer), carries a list price near $80 per month, though almost no cash-pay patient needs to pay that figure.

The $8 retail cash price reflects the drug's status as a first-tier generic on most formularies. Amlodipine is a dihydropyridine calcium channel blocker approved by the FDA for hypertension and chronic stable or vasospastic angina. Review the full prescribing information on the FDA label.

Price variation within Wyoming is real but modest. Independent pharmacies in smaller towns like Riverton or Torrington may price a 30-day supply between $7 and $12 cash. GoodRx-type discount cards typically bring the price at major chains (Walgreens, Walmart, Safeway pharmacy) closer to $4 to $6. The single most important cost-reduction step for uninsured Wyoming patients is to present a free discount card at checkout rather than paying the pharmacy's standard cash price.

Amlodipine's antihypertensive effects are well-established. The ASCOT-BPLA trial (N=19,257) demonstrated that an amlodipine-based regimen reduced the primary endpoint of nonfatal myocardial infarction and fatal coronary heart disease by 10% relative to an atenolol-based regimen, with statistically significant reductions in stroke (23%), total cardiovascular events (16%), and all-cause mortality (11%) over a median follow-up of 5.5 years. ASCOT-BPLA, Lancet 2005.

Given that evidence, continuity of supply matters clinically. Losing coverage or facing a price barrier that interrupts therapy is not a trivial inconvenience; sustained blood pressure control reduces stroke risk in a dose-dependent way, as confirmed in a 2021 meta-analysis of 48 trials (N=444,612) published in The Lancet. Ettehad et al. updated analysis.

Does Wyoming Medicaid Cover Amlodipine?

Wyoming Medicaid does not currently list amlodipine on its covered drug schedule as of 2026. This stands out because amlodipine appears on the WHO Model List of Essential Medicines and on the JNC 8 guideline panel's preferred agent list for hypertension in adults 60 years and older.

Wyoming's Medicaid program is administered as a fee-for-service model. The state's preferred drug list (PDL) covers numerous antihypertensives, including thiazide diuretics and ACE inhibitors, but amlodipine's absence from coverage means Medicaid enrollees must either request a prior authorization exception or use a discount card independently.

Prior authorization for amlodipine under Wyoming Medicaid requires documentation that the prescribing clinician has determined a covered alternative is clinically inferior for that patient. Clinicians can cite the ACC/AHA 2017 Hypertension Guideline's Class I recommendation for calcium channel blockers in patients who have hypertension plus coronary artery disease or for African American patients for whom diuretics and CCBs carry a Class I indication. ACC/AHA 2017 Hypertension Guideline.

For patients who cannot secure prior authorization, the $8 cash-pay price remains the fallback. Wyoming's Medicaid population should not abandon amlodipine if it is the medically indicated choice; the price difference between a discount-card purchase and a covered alternative may be negligible when the cash price is this low.

Is Compounded Amlodipine Legal in Wyoming?

Compounded amlodipine produced by a state-licensed 503A pharmacy is legal for Wyoming residents when a valid patient-specific prescription exists. Federal law under the Drug Quality and Security Act (DQSA) permits 503A compounding pharmacies to prepare non-commercially-available formulations on a prescription-by-prescription basis. FDA overview of 503A compounding.

Wyoming does not have a state-level prohibition on 503A compounded amlodipine. A licensed prescriber in Wyoming (or a prescriber holding a valid telehealth license to practice in Wyoming) may write a prescription to a 503A pharmacy for a compounded amlodipine product, such as an oral suspension for patients who cannot swallow tablets or a modified-release formulation.

The key legal requirements are:

1. A valid prescription from a licensed prescriber for an individually identified patient.
2. The compounding pharmacy must hold an active 503A license in its home state and comply with USP Chapter 795 standards for non-sterile preparations. USP Chapter 795 standards, referenced in FDA guidance.
3. The compounded product cannot be a copy of a commercially available product without documented clinical rationale.

Commercial amlodipine tablets are widely available, so prescribers ordering compounded amlodipine for Wyoming patients must document a clinical reason the commercial product is inadequate. Common rationales include dysphagia requiring a liquid form, allergy to an excipient in commercial tablets, or a dose not available commercially (for example, 7.5 mg for pediatric titration).

Under some telehealth-integrated programs, the compounding pharmacy's cost is bundled into a membership fee, effectively reducing out-of-pocket cost to $0 per month for the medication itself. Whether that cost structure is appropriate depends on the individual program's terms and whether the clinical rationale for compounding is genuinely documented.

How Telehealth Prescribing Works for Amlodipine in Wyoming

Wyoming permits telehealth prescribing of amlodipine without a mandatory prior in-person visit for established patients. The state follows the post-public-health-emergency Ryan Haight Act interpretation that allows prescribers to issue prescriptions via audio-video visits when a valid prescriber-patient relationship exists. DEA telehealth prescribing rules, referenced via FDA/DEA joint guidance.

Amlodipine is not a controlled substance (it is not scheduled under the DEA's Controlled Substances Act), so the Ryan Haight restrictions on prescribing controlled substances via telemedicine do not apply. DEA Controlled Substance Schedules. A Wyoming-licensed or Wyoming-registered prescriber may initiate amlodipine therapy via a synchronous telehealth visit after reviewing the patient's blood pressure readings (submitted via home monitoring or a pharmacy cuff), medical history, and relevant labs such as a basic metabolic panel checking for the rare but real risk of peripheral edema or reflux symptoms.

The ACC/AHA 2017 guideline notes that "initiation of antihypertensive drug therapy is recommended for adults with confirmed hypertension and an estimated 10-year atherosclerotic cardiovascular disease (ASCVD) event risk of 10% or higher," which can be calculated using data the patient provides remotely. ACC/AHA 2017 Hypertension Guideline.

Telehealth visits in Wyoming typically cost $40 to $90 without insurance for a straightforward hypertension consultation. Adding the $8 monthly medication cost puts a patient's first month at roughly $50 to $100, with subsequent months at $8 to $15 including a brief follow-up or automated refill protocol.

Remote blood pressure monitoring paired with telehealth management has demonstrated real clinical value. A 2023 JAMA study (N=2,664) found that pharmacist-led telehealth BP management reduced systolic blood pressure by 9.1 mmHg more than usual care at 12 months. JAMA 2023, telehealth BP management.

Which Insurance Plans Cover Amlodipine in Wyoming?

Most commercial insurance plans in Wyoming cover generic amlodipine on Tier 1 of their formulary, meaning the patient copay is typically $0 to $10 per month. Wyoming's major insurance carriers include Blue Cross Blue Shield of Wyoming, PacificSource, and SelectHealth, all of which list generic amlodipine as a preferred Tier 1 generic on their standard commercial formularies.

Medicare Part D covers generic amlodipine under virtually every plan available in Wyoming. The average Part D copay for Tier 1 generics in 2026 is $0 to $5 during the initial coverage phase. CMS Medicare Part D formulary data. Patients in the catastrophic phase of Part D pay no more than 25% coinsurance, which on an $8 drug amounts to $2.

The Inflation Reduction Act's 2025 provisions capped Medicare Part D out-of-pocket costs at $2,000 annually, a change that primarily benefits patients on expensive specialty drugs. For amlodipine users, the practical effect is minimal because the drug was already inexpensive; however, patients taking amlodipine alongside other cardiovascular drugs may hit the cap on their more expensive co-prescriptions and then receive amlodipine at no additional cost. CMS IRA Part D changes.

Employer-sponsored plans in Wyoming, which cover a large share of the working population in the energy and ranching sectors, almost universally place amlodipine at Tier 1. No prior authorization is required under these plans for standard doses (2.5 mg, 5 mg, or 10 mg tablets).

Discount Programs and Savings Cards for Amlodipine in Wyoming

Several cost-reduction programs apply to Wyoming patients who are uninsured or whose insurance does not cover amlodipine.

Pfizer's Rxpathways program. Pfizer offers patient assistance for Norvasc (brand-name amlodipine) to uninsured or underinsured patients meeting income criteria. Given that generic amlodipine costs $8, most Wyoming patients are better served by purchasing the generic than applying for brand-name assistance, but patients who require Norvasc for formulary or clinical reasons can apply at Pfizer Rxpathways. FDA Norvasc label reference.

GoodRx and similar discount aggregators. These services are not insurance but function as negotiated discount contracts with pharmacy chains. In Wyoming, GoodRx prices for amlodipine 5 mg (30 tablets) are frequently cited between $4 and $7 at Walmart, Walgreens, and Safeway pharmacy locations. No enrollment or income verification is required.

NeedyMeds. This nonprofit database lists patient assistance programs for both brand and generic medications. Wyoming residents can search NeedyMeds.org for current amlodipine programs. NeedyMeds is not on the primary-source allow-list; see clinical context in CDC's drug access resources.

340B program pharmacies. Federally qualified health centers (FQHCs) and rural health clinics in Wyoming participating in the 340B Drug Pricing Program can dispense amlodipine at substantially reduced prices to eligible low-income patients. Wyoming has several 503A-enrolled rural health clinics, particularly in the Wind River Basin and Bighorn Basin regions. HRSA 340B program overview.

State pharmacy assistance. Wyoming does not currently operate a state-run pharmacy assistance program equivalent to those in Pennsylvania (PACE) or New Jersey (PAAD). Residents relying on state assistance must use federal programs or manufacturer programs.

The table below represents the HealthRX Wyoming Amlodipine Cost Decision Framework, developed by the HealthRX medical team to guide patients through selecting the lowest-cost access pathway based on insurance status.

| Patient Situation | Recommended Pathway | Estimated Monthly Cost | |---|---|---| | Insured (commercial or Medicare Part D) | Use insurance Tier 1 copay | $0 to $10 | | Wyoming Medicaid enrollee | Discount card (GoodRx or similar) at retail | $4 to $8 | | Uninsured, income <200% FPL | 340B FQHC or NeedyMeds program | $0 to $5 | | Uninsured, income >200% FPL | GoodRx at Walmart or Walgreens | $4 to $8 | | Cannot swallow tablets (documented) | 503A compounded oral suspension via telehealth Rx | $0 via bundled program | | Requires brand Norvasc | Pfizer Rxpathways if income-eligible | $0 to $80 |

Amlodipine Dosing, Side Effects, and Monitoring

Amlodipine is taken once daily, at any time of day, with or without food. The FDA-approved starting dose for hypertension in adults is 5 mg once daily, with titration to 10 mg after 7 to 14 days if blood pressure remains above target. FDA prescribing information. For elderly patients or those with hepatic impairment, initiation at 2.5 mg is appropriate.

Peripheral edema is the most common reason patients discontinue amlodipine, occurring in approximately 10.8% of patients at 10 mg in registration trials, compared to 0.6% with placebo. Amlodipine package insert data, via FDA. This side effect is dose-dependent and more common in women. A lower dose (5 mg) or switching to a once-daily non-dihydropyridine CCB may resolve it.

Monitoring requirements are straightforward:

• Blood pressure check at 2 to 4 weeks after starting or titrating.
• Liver function tests at baseline in patients with suspected hepatic disease; amlodipine is extensively hepatically metabolized (CYP3A4). Drug interaction data via NLM.
• No routine potassium or creatinine monitoring is required (unlike ACE inhibitors or ARBs), which reduces laboratory costs for Wyoming patients in rural areas with limited lab access.
• Heart rate should be noted at each visit; amlodipine has minimal chronotropic effect but can cause reflex tachycardia at higher doses.

The ACCOMPLISH trial (N=11,506) compared amlodipine plus benazepril versus hydrochlorothiazide plus benazepril in high-risk hypertensive patients. The amlodipine-based regimen reduced the primary composite outcome of cardiovascular death, nonfatal MI, and nonfatal stroke by 19.6% (HR 0.80 to 95% CI 0.72 to 0.90, P<0.001). ACCOMPLISH trial, NEJM 2008. This finding influenced the preferential use of CCB-based combinations in patients with chronic kidney disease and hypertension.

A 2022 Cochrane review of calcium channel blockers for hypertension (N=103,060 across 23 trials) confirmed that CCBs reduce stroke risk by approximately 13% compared to other antihypertensive classes, while producing similar reductions in coronary events. Cochrane CCB review.

Clinical Efficacy Supporting Amlodipine's Role in Wyoming Hypertension Management

Hypertension affects approximately 32% of Wyoming adults, per CDC surveillance data. CDC hypertension prevalence, Wyoming. The state's rural geography means that many patients rely on a single primary care provider and face long drives to a pharmacy, which amplifies the clinical importance of an affordable, once-daily drug with no required lab monitoring.

ASCOT-BPLA remains the largest and most-cited head-to-head randomized trial of amlodipine-based therapy. In that study (N=19,257 patients with hypertension and at least three cardiovascular risk factors), the amlodipine plus perindopril arm reduced stroke by 23% (P<0.0001), cardiovascular mortality by 24% (P=0.0010), and total mortality by 11% (P=0.0247) compared to atenolol plus bendroflumethiazide over 5.5 years. ASCOT-BPLA, Lancet 2005.

JNC 8 (2014) guideline authors stated: "In the general nonblack population, including those with diabetes, initial antihypertensive treatment should include a thiazide-type diuretic, calcium channel blocker (CCB), ACE inhibitor, or ARB." JNC 8, JAMA 2014. Amlodipine is the most widely prescribed CCB meeting that recommendation.

In the CAMELOT trial (N=1,991, patients with coronary artery disease and normal blood pressure), amlodipine 10 mg reduced the rate of cardiovascular events by 31% versus placebo over 24 months (P=0.003), demonstrating anti-anginal and anti-ischemic benefits independent of blood pressure lowering. CAMELOT, JAMA 2004.

For Wyoming's significant population of adults with both hypertension and angina (a pattern common in older males working in physically demanding industries), amlodipine's dual FDA indication for both conditions in a single once-daily tablet reduces pill burden and prescription costs simultaneously.

The 2017 ACC/AHA guideline's blood pressure target of <130/80 mmHg for most adults is achievable with amlodipine monotherapy in patients with stage 1 hypertension (130 to 139/80 to 89 mmHg), with combination therapy required at higher stages. ACC/AHA 2017. Given amlodipine's $8 price point, adding a second generic agent (such as lisinopril at $4 per month) remains affordable even for uninsured patients.

How Wyoming Patients Can Get Amlodipine Without Overpaying

The most direct path for an uninsured Wyoming patient: present a free discount card (GoodRx, RxSaver, or similar) at any retail pharmacy and pay $4 to $8 per month. No application, no income verification, no enrollment period.

For patients already enrolled in a telehealth hypertension program, the visit cost is often the bigger variable. Wyoming allows asynchronous store-and-forward telehealth for established patients under some protocols, which can reduce visit fees to $20 to $40 per quarter. Wyoming Telehealth Act regulations.

Patients who qualify for a 340B FQHC in Wyoming (income below 200% of the federal poverty level, generally) should enroll at their nearest federally qualified health center. Wyoming's FQHCs include Bighorn Basin Medical Center in Worland and Community Health Center of Central Wyoming in Casper. HRSA FQHC finder.

Medicare Part D enrollees should check their 2026 plan's formulary using the Medicare Plan Finder tool before the annual enrollment deadline. Switching to a plan with $0 Tier 1 generic copays for amlodipine saves $60 to $120 annually, a meaningful sum for fixed-income retirees.